Company patents
TEVA PHARMACEUTICALS INTERNATIONAL GMBH
TEVA PHARMACEUTICALS INTERNATIONAL GMBH's patent strategy shows a surprising shift, with significant declines in core areas like Heterocyclic Compounds (67.1% of portfolio) and General Organic Chemistry Methods (52.6% of portfolio), both experiencing over 25% YoY declines in 2025 and a complete halt so far in 2026. This contrasts with a brief surge in Pharmaceutical Preparations, which saw a 140.0% YoY growth in 2024 before a subsequent decline, indicating a potential re-evaluation of its R&D focus within its dominant pharma_biotech sector.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
76 US filings (since 2023) · 8 categories · 9 themes
Techniques for preparing and characterizing specific solid forms, such as crystal forms, salts, co-crystals, or amorphous forms, of active pharmaceutical ingredients to optimize properties like stability, solubility, and bioavailability.
Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.
Methods and intermediates for preparing complex organic molecules intended as active pharmaceutical ingredients (APIs), often involving multi-step synthesis and optimization of reaction pathways.
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Processes and methodologies for the efficient and scalable preparation of complex heterocyclic compounds and their precursors, including specific reaction conditions, purification techniques, and intermediate compounds.
Mechanical or electromechanical systems designed for precise, often self-administered, delivery of medicaments, including features for dose setting, needle insertion/retraction, and safety mechanisms to prevent premature activation.
Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.
Development and application of therapeutic proteins or peptides produced through recombinant DNA technology, including fusion proteins and modified growth factors.
Development of materials with tailored porosity, surface chemistry, or structure, such as metal-organic frameworks (MOFs), zeolites, or superficially porous particles, for selective adsorption, ion exchange, or chromatographic separations.
Patents
Showing 1-10 of 83
API Solid Form Engineering